|1.||Chau, Albert: 1 article (11/2011)|
|2.||Acton, Gary: 1 article (11/2011)|
|3.||Komisarenko, Volodymyr: 1 article (11/2011)|
|4.||Manikhas, Alexei: 1 article (11/2011)|
|5.||Bondarenko, Ihor: 1 article (11/2011)|
|6.||Jones, David: 1 article (11/2011)|
|7.||Yariz, Kemal O: 1 article (11/2011)|
|8.||Erlandsson, Fredrik: 1 article (11/2011)|
|9.||Senderovich, Shai: 1 article (11/2011)|
|10.||Pegram, Mark: 1 article (11/2011)|
|1.||Breast Neoplasms (Breast Cancer)
03/02/2010 - "HuHMFG1 (AS1402) is a humanised monoclonal antibody that has undergone a phase I trial in metastatic breast cancer. "
03/02/2010 - "Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer."
01/01/2009 - "A phase II study is ongoing to evaluate the clinical activity of AS1402 in patients with advanced breast cancer. "
01/01/2009 - "Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer."
11/01/2011 - "We compared the outcomes of patients with breast cancer treated with letrozole with or without AS1402. "
01/01/2009 - "Patients received AS1402 over a 1- to 3-hour intravenous (i.v.) infusion at doses between 1 and 16 mg/kg, with repeated dosing every 1 to 3 weeks (based on patient-individualized PK assessment) until disease progression. "
11/01/2011 - "The study was stopped early because of a trend toward worse response rates and a higher rate of early disease progression in the AS1402 + letrozole arm. "
|2.||Immunoglobulin G (IgG)